- Home
- LNSR vs QNCX Comparison
LNSR vs QNCX Comparison
Compare LNSR & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNSR
- QNCX
- Stock Information
- Founded
- LNSR 2004
- QNCX 2012
- Country
- LNSR United States
- QNCX United States
- Employees
- LNSR N/A
- QNCX N/A
- Industry
- LNSR Medical Electronics
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LNSR Health Care
- QNCX Health Care
- Exchange
- LNSR Nasdaq
- QNCX Nasdaq
- Market Cap
- LNSR N/A
- QNCX 44.0M
- IPO Year
- LNSR N/A
- QNCX 2019
- Fundamental
- Price
- LNSR $13.81
- QNCX $1.03
- Analyst Decision
- LNSR Hold
- QNCX Strong Buy
- Analyst Count
- LNSR 1
- QNCX 5
- Target Price
- LNSR $15.00
- QNCX $8.00
- AVG Volume (30 Days)
- LNSR 130.3K
- QNCX 511.8K
- Earning Date
- LNSR 05-08-2025
- QNCX 05-16-2025
- Dividend Yield
- LNSR N/A
- QNCX N/A
- EPS Growth
- LNSR N/A
- QNCX N/A
- EPS
- LNSR N/A
- QNCX N/A
- Revenue
- LNSR $57,065,000.00
- QNCX N/A
- Revenue This Year
- LNSR $29.95
- QNCX N/A
- Revenue Next Year
- LNSR $29.35
- QNCX N/A
- P/E Ratio
- LNSR N/A
- QNCX N/A
- Revenue Growth
- LNSR 26.87
- QNCX N/A
- 52 Week Low
- LNSR $3.21
- QNCX $0.51
- 52 Week High
- LNSR $17.31
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- LNSR 49.37
- QNCX 38.67
- Support Level
- LNSR $13.65
- QNCX $0.98
- Resistance Level
- LNSR $14.12
- QNCX $1.16
- Average True Range (ATR)
- LNSR 0.14
- QNCX 0.09
- MACD
- LNSR -0.03
- QNCX 0.01
- Stochastic Oscillator
- LNSR 26.23
- QNCX 22.22
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.